肾透明细胞癌组织IRS-5和IRS-6表达及其临床意义的探讨

目的：探讨肾透明细胞癌组织和对应癌旁正常组织中胰岛素受体底物IRS-5和IRS-6基因表达差异及其临床意义。方法：收集经病理确诊的52例肾透明细胞癌患者标本，取肾癌组织和对应的癌旁正常组织，采用实时荧光定量PCR法检测IRS-5和IRS-6基因的表达，并分析两者与临床病理参数之间的关系。结果：IRS-5在肾透明细胞癌组织中的表达水平显著高于对应癌旁正常组织（0．864±0．112VS0．762±0．104），P=0．021。IRS-5mRNA的表达与肿瘤大小、临床分期及病理分级相关，P〈0．05；而与患者年龄、性别无关，P〉0．05。IRS-6在肾透明细胞癌组织和对应癌旁正常组织中均有表达，两者比较差异无统计学意义（01647±0．116vs0．6124±0．122），P＝0．32。IRS-6mRNA的表达与患者年龄、性别、肿瘤大小、病理分级及临床分期亦无相关性，P〉0．05。结论：IRS－5基因在肾透明细胞癌中过表达，可能与肿瘤发生发展有关，对临床评价肿瘤恶性度有一定价值；IRS－6基因在肾透明细胞癌和癌旁组织中表达无差异，提示IRS－6基因在肾透明细胞癌中可能不起作用。

IRS-5 and IRS-6 expression and clinical significance in clear cell renal cell carcinoma

OBJECTIVE：To explore the expression of IRS-5 and IRS-6 gene in clear cell renal cell carcinoma （RCC） and evaluate its clinic significance. METHODS： A series of 52 pathologically diagnosed RCC with matched normal coun- terpart tissues from the same individual were collected. The expression of IRS-5 and IRS-6 mRNA in RCC tissues and corresponding noncancerous tissues were detected by real-time fluorescent quantitative PCR and their correlation with clin- ico-pathologic parameters were analyzed. RESULTS： The mRNA level of IRS-5 was significantly higher in RCC tissues than that in corresponding noncancerous tissues. There was significant difference between them （0.864± 0. 112 vs 0. 762±0. 104,P=0. 021）. The level of IRS-5 mRNA was related with the stage,tumor size and the pathological grade but it wasn＇t related with the age,gender of the patients. The mRNA of IRS-6 was presented both in RCC specimens and adjacent normal renal tissues. There was no significant difference between them （0. 647±0. 116 vs 0. 612±0. 122,P= 0.32）. The expression of hIR-S6 wasn＇t related with any clinico-pathologie characteristics. CONCLUSIONS： It has demonstrated that high expression of IRS-5 existe in RCC and it may be related to the development of tumor. The IRS-6 may not take part in that process. The clinic relevance and the mechanism of altered IRS-5 expression in RCC need further exploration.